A vaccine that can prevent the damage to pancreatic β-cells in patients with type I diabetes has long been the Holy Grail of diabetes research.
That goal has now come a step closer with the publication of a Phase II study showing that a reverse...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?